Log in

ONCO Oncopeptides AB OMXSTO · Sweden

Oncopeptides AB (ONCO) news ONCO reverse split, delisting and offering news

Latest Oncopeptides AB news

  1. Company Updates

    Onconetix provides $2.5 million bridge advance to Realbotix before acquisition

    The bridge facility provides up to $5,000,000 to Realbotix LLC, the target of a pending all-stock share exchange, with an initial advance of $2,500,000.

  2. Financings

    Onconetix sells $30,249,600 of Series F preferred in PIPE financing

    The securities purchase agreement covers 37,812 shares of Series F convertible preferred stock with an initial conversion price of $0.9767 per share.

  3. Listings

    Onconetix to effect 1-for-10 reverse stock split on May 21, 2026

    The Board fixed the ratio under a stockholder authority approved April 30, 2026, to help keep the stock above Nasdaq's $1.00 minimum bid price.

  4. Company Updates

    Onconetix reports Q1 2026 progress at Proteomedix

    The Swiss unit added two peer-reviewed papers, began enrolling in a U.S. validation study with Labcorp and kept expanding sales in Europe. The release does not report quarterly revenue or cash.

  5. Company Updates

    Onconetix directors Oakley and Meier resign; Dorf named chairman

    Josh Epstein joined the board on April 23, 2026 and chairs its Nominating and Corporate Governance Committee. The 8-K says neither resignation involved a disagreement with management.

  6. Financings

    Onconetix sells convertible preferred and warrants for approximately $6.25 million

    Institutional investors bought 7,813 shares of Series E convertible preferred stock and warrants for 2,025,223 common shares. The preferred converts at $3.8576.

  7. Mergers

    Onconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%

    Onconetix holders would keep 10% of the combined company. Closing was expected in the fourth quarter of 2025, subject to regulatory, stockholder and third-party approvals.

  8. Listings

    Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone

    Nasdaq flagged the missing quarterly report on May 20, 2025 as another basis for delisting, ahead of a Panel hearing set for May 27, 2025. Onconetix also issued a promissory note to Keystone Capital Partners for a $250,000.00 purchase price.

  9. Distress

    Onconetix files NT 10-K late filing notice, says cash fell to $0.6 million at year end

    Onconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities.

  10. Distress

    Onconetix delays 10-K as cash falls to $0.6 million at year end

    The company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023.

What Oncopeptides AB does

Onconetix, Inc. describes itself as a commercial stage biotechnology company focused on men's health and oncology. Its main product is Proclarix, a protein-based blood test for prostate cancer that uses the same sample as a regular PSA test. Proclarix helps doctors and patients with unclear PSA results decide whether a biopsy is needed. It is approved for sale in the European Union under the In Vitro Diagnostic Regulation, and the company expects to market it in the United States as a lab developed test through its license agreement with LabCorp. Onconetix acquired ENTADFI, an FDA-approved once-daily pill for BPH, in April 2023, but abandoned its commercialization and no longer holds inventory of the product. The company relies on third-party manufacturers, with single-source suppliers for commercial product. As of December 31, 2025, it reported cash of approximately $5.2 million, and the filing states that substantial doubt exists about its ability to continue as a going concern. In February 2026 it entered into a share exchange agreement with Realbotix Corp.

Product or programWhat it isStage
ProclarixBlood test to help diagnose prostate cancer in patients with unclear PSA resultsApproved for sale in the European Union
ENTADFIOnce-daily finasteride and tadalafil pill for BPHFDA-approved; commercialization abandoned

Summarised from the company's 10-K filed Mar 13, 2026.

Oncopeptides AB annual financials

LineFY2025FY2024
Revenue$815,371$2.5 million
Research and development$154,359
Net income (loss)-$14.0 million-$58.7 million
Cash from operations-$9.7 million-$10.5 million
Cash and equivalents$5.2 million$646,500

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Oncopeptides AB

Did Oncopeptides AB do a reverse stock split?

Our latest story on this, dated Oct 26, 2026: "Onconetix sets a 1-for-10 reverse stock split for November 6". The story links the filing or release it is based on. Read the story.

Was Oncopeptides AB delisted?

Our latest story on this, dated May 22, 2025: "Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone". The story links the filing or release it is based on. Read the story.

Has Oncopeptides AB raised money recently?

Our latest story on this, dated Jul 28, 2026: "Onconetix sells $30,249,600 of Series F preferred in PIPE financing". The story links the filing or release it is based on. Read the story.

Has Oncopeptides AB sold convertible notes?

Our latest story on this, dated Jul 28, 2026: "Onconetix sells $30,249,600 of Series F preferred in PIPE financing". The story links the filing or release it is based on. Read the story.

Has Oncopeptides AB received a Nasdaq deficiency notice?

Our latest story on this, dated May 22, 2025: "Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone". The story links the filing or release it is based on. Read the story.

Is Oncopeptides AB involved in a merger or acquisition?

Our latest story on this, dated Jul 16, 2025: "Onconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Oncopeptides AB?

Oncopeptides AB trades under the ticker ONCO on OMXSTO.

Where is Oncopeptides AB listed?

Oncopeptides AB is listed on OMXSTO. Our directory also records these other listings: GETTEX:OND; LSIN:0RN4; LSX:A2DLU2.

Which country or territory is Oncopeptides AB listed under?

Our directory records Oncopeptides AB under Sweden.

What does Oncopeptides AB do?

Our directory classifies Oncopeptides AB as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Oncopeptides AB?

The ISIN recorded for Oncopeptides AB is SE0009414576.

Does aibio.space cover Oncopeptides AB?

aibio.space lists Oncopeptides AB among 2,820 public biotech companies and publishes its news here as stories appear.

What does Oncopeptides AB develop?

Onconetix, Inc. describes itself as a commercial stage biotechnology company focused on men's health and oncology. Its main product is Proclarix, a protein-based blood test for prostate cancer that uses the same sample as a regular PSA test.

What is Proclarix from Oncopeptides AB?

Proclarix: Blood test to help diagnose prostate cancer in patients with unclear PSA results Stage: Approved for sale in the European Union.

What is ENTADFI from Oncopeptides AB?

ENTADFI: Once-daily finasteride and tadalafil pill for BPH Stage: FDA-approved; commercialization abandoned.

Investor discussion: Oncopeptides AB

Members talk about Oncopeptides AB (ONCO). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Oncopeptides AB, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source

  2. Mergers

    Filed documents for a merger or acquisition. SEC Form 425. Source

  3. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  4. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  5. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source

  6. Mergers

    Filed documents for a merger or acquisition. SEC Form 425. Source

  7. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source

  8. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source

  9. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  10. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source

  11. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  12. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

  13. Mergers

    Filed documents for a merger or acquisition. SEC Form 425. Source

  14. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source

  15. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  16. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  17. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  18. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  19. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source

  20. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). Source

  21. Mergers

    Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,8.01,9.01). Source

  22. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source

  23. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 1.01,2.03,3.03,5.03,7.01,9.01). Source

  24. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source

  25. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,9.01). Source

  26. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  27. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source

  28. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). Source

  29. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  30. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OMXSTO:ONCO on TradingView.

Listing details

Oncopeptides AB is a public biotech or pharmaceutical company listed on OMXSTO under the ticker ONCO, recorded under Sweden. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Oncopeptides AB
Ticker
ONCO
Listing
OMXSTO
Country or territory
Sweden
Business scope
Pharmaceuticals: Major
ISIN
SE0009414576
Other listed symbols
GETTEX:OND; LSIN:0RN4; LSX:A2DLU2
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.